- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02734459
A Bioequivalence Study to Compare the Pharmacokinetics (PK) Of Marketed Product TobraDex® To An Experimental Ophthalmic Sterile Ointment Containing Tobramycin And Dexamethasone In Aqueous Humor In Patients Undergoing Indicated Cataract Surgery (TBO)
April 5, 2016 updated by: Semler Research Center Pvt. Ltd.
A Multi Center, Open Label, Randomized, Two- Treatment, Single Dose, Crossover, Bioequivalence Study To Compare The Pharmacokinetics Of Marketed Product TobraDex® (Tobramycin And Dexamethasone Ophthalmic Ointment) To An Experimental Ophthalmic Sterile Ointment Containing Tobramycin 0.3% And Dexamethasone 0.1% W/W In Aqueous Humor In Patients Undergoing Indicated Cataract Surgery
Each patient will be randomized to receive one dose of the test article in one eye and one dose of the reference formulations in the contralateral eye.
One eye will be selected as the initial eye for cataract surgery and aqueous humor collection and hence will be dosed and operated on first.
Followed by the second eye which will be dosed no early than a week followed by aqueous humor collection as per specified time points and no later than 35 days following the first eye again prior to the cataract surgery.
Study Overview
Study Type
Interventional
Enrollment (Actual)
756
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Be male or female 18 years of age and above
- Presence of visually significant cataracts in both eyes
- Have a chief complaint consistent with visually significant cataracts
- Be able to communicate effectively with the study personnel and be able to understand and follow directions
- Be medically fit with clinically acceptable laboratory profiles and ECG
- Be willing to carry out the required pre op directions and post op care and be able to make the scheduled appointment
- Have given the written informed consent for participation in the study
- In addition, female patients of child bearing potential age must have a negative urine pregnancy test
Exclusion Criteria:
- Participation in any ophthalmic indicative bioavailability/ bioequivalence/ Pharmacokinetic study or received an ophthalmic indicative investigational drug within a period of three months prior to screening
- Presence or history of recent viral corneal disorder or active corneal condition which is contraindicated.
- Presence or history of uveitis or uveitis
- Presence of retinal disorders
- Ocular trauma within three months of the trial
- Patients who had received topical and or systemic/ oral steroids
- Uncontrolled diabetes
- History of any allergies
- Known hypersensitivity or allergy to TobraDex® in combination or its components
- Clinical laboratory test values outside the acceptable reference range and when confirmed on re-examination deemed to be clinically significant as determined by the investigator(s)
- Clinically significant illness during 3 weeks prior to Visit 1 (as determined by the investigators)
- Presence of a clinically significant systemic disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: tobramycin and dexamethasone ophthalmic test ointment
The test drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in one eye before the cataract surgery.
|
the patient will be dosed with the study drug into the "V" pocket is formed between the eye ball and the lower eyelid during cataract surgery.
|
Active Comparator: TobraDex® ointment
The reference drug (tobramycin is an aminoglycoside antibiotic and dexamethasone is a corticosteroid) will be administered in another eye before the cataract surgery.
|
the patient will be dosed with the study drug into the "V" pocket is formed between the eye ball and the lower eyelid during cataract surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Concentration of dexamethasone in aqueous humor at different time points after administration of a single dose of each of the two drugs.
Time Frame: 30 min - 8 hours
|
A series of aqueous humor samples will be collected from each eye of each patient.
|
30 min - 8 hours
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time at which maximum mean drug concentration (Tmax) is achieved, in aqueous humor after the administration of test and reference drugs.
Time Frame: 30 min - 8 hours
|
30 min - 8 hours
|
AUC under the concentration-time curve from time-zero to the time t for test and reference drugs
Time Frame: 30 min - 8 hours
|
30 min - 8 hours
|
Maximum drug concentration (Cmax) achieved, in aqueous humor after the administration of test and reference drugs.
Time Frame: 30 min - 8 hours
|
30 min - 8 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2013
Primary Completion (Actual)
October 1, 2015
Study Completion (Actual)
March 1, 2016
Study Registration Dates
First Submitted
March 24, 2016
First Submitted That Met QC Criteria
April 5, 2016
First Posted (Estimate)
April 12, 2016
Study Record Updates
Last Update Posted (Estimate)
April 12, 2016
Last Update Submitted That Met QC Criteria
April 5, 2016
Last Verified
April 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- S-10-084
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bilateral Cataract
-
Carolina Eyecare Physicians, LLCAbbott Medical Optics; Science in VisionCompletedCataract Bilateral | Astigmatism BilateralUnited States
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompleted
-
Gemini Eye ClinicRecruitingBilateral Cataract | Unilateral CataractCzechia
-
Beaver-Visitec International, Inc.Completed
-
University of PlymouthCarl Zeiss Meditec AG; University Hospital Plymouth NHS Trust; Glasgow Caledonian... and other collaboratorsRecruitingCataract Bilateral | Astigmatism BilateralUnited Kingdom
-
Sloan W. Rush, MDCompleted
-
Alcon ResearchCompleted
-
Center For SightScience in VisionCompleted
-
SIFI SpACompletedAstigmatism | Bilateral CataractSpain, France, Germany
-
Carolina Eyecare Physicians, LLCJohnson & Johnson Surgical Vision, Inc.; Science in VisionCompletedPresbyopia | Cataract BilateralUnited States
Clinical Trials on cataract surgery
-
Iladevi Cataract and IOL Research CenterCompletedCataract Surgery | Shallow Anterior Chamber | PhacoemulsificationIndia
-
Technolas Perfect Vision GmbHCompletedCataractCzech Republic, India
-
University of OklahomaCompletedPrimary Open Angle Glaucoma | Cataract | Pigmentary GlaucomaUnited States
-
Technolas Perfect Vision GmbHCompletedCataractCzech Republic, India
-
Glaukos CorporationCompletedOpen-Angle GlaucomaUnited States
-
Ziemer Ophthalmic Systems AGRecruiting
-
Technolas Perfect Vision GmbHCompleted
-
Sun Yat-sen UniversityCompleted
-
Guy's and St Thomas' NHS Foundation TrustCompletedCataract | Surgery
-
University Hospital, BordeauxCompleted